We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
+$224M
Cap. Flow %
9.21%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Miscellaneous 82.86%
2 Healthcare 14.52%
3 Energy 1.33%
4 Technology 0.46%
5 Materials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMNN icon
351
Imunon
IMNN
$7.86M
$128K 0.01%
28
-203
-88% -$1.21M
ATNM icon
352
Actinium Pharmaceuticals
ATNM
$39.3M
$121K 0.01%
+2,281
New +$152K
SGMO
353
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$121K 0.01%
215
-8,906
-98% -$73.4K
ECYT
354
DELISTED
Endocyte, Inc. Common Stock
ECYT
$121K 0.01%
+26,423
New +$138K
ADAP
355
DELISTED
Adaptimmune Therapeutics
ADAP
$120K ﹤0.01%
+10,004
New +$141K
OCGN icon
356
Ocugen
OCGN
$337M
$110K ﹤0.01%
458
– –
IMUX icon
357
CALL
Immunic
IMUX
$141M
$101K ﹤0.01%
+1
New +$5K
IMNN icon
358
PUT
Imunon
IMNN
$7.86M
– –
0
– –
SEEL
359
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
ORMP icon
360
Oramed Pharmaceuticals
ORMP
$192M
$58K ﹤0.01%
10,558
-201,459
-95% -$1.27M
TLPH icon
361
PUT
Talphera
TLPH
$61.8M
$57K ﹤0.01%
9
– –
KERX
362
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$56K ﹤0.01%
158
-30
-16% -$201
PLUR icon
363
PUT
Pluri
PLUR
$14.4M
$53K ﹤0.01%
4
-45
-92% -$7.81K
TLPH icon
364
CALL
Talphera
TLPH
$61.8M
$52K ﹤0.01%
9
-74
-89% -$6.08K
IPCI
365
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$47K ﹤0.01%
19
-64
-77% -$1.68K
OPXAW
366
DELISTED
Opexa Therapeutics, Inc.
OPXAW
$46K ﹤0.01%
382,765
-162,740
-30% -$19.8K
XOMA
367
CALL
DELISTED
Xoma
XOMA
$38K ﹤0.01%
25
-278
-92% -$8.77K
CHL
368
CALL
DELISTED
China Mobile Limited
CHL
$19K ﹤0.01%
481
-78
-14% -$4.81K
SEEL
369
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
BPTH
370
DELISTED
Bio-Path Holdings Inc
BPTH
$17K ﹤0.01%
4
+1
+33% +$4.69K
ALBO
371
PUT
DELISTED
Albireo Pharma Inc
ALBO
$8K ﹤0.01%
6
– –
AMG icon
372
PUT
Affiliated Managers Group
AMG
$9B
– –
-238
Closed -$5.2M
ANIP icon
373
CALL
ANI Pharmaceuticals
ANIP
$1.66B
– –
-400
Closed -$2.48M
BNBX
374
DELISTED
BNB PLUS CORP
BNBX
– –
0
– -$289K
AR icon
375
Antero Resources
AR
$11.9B
– –
-8,580
Closed -$246K
13 14
15
16 17

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management deployed $224M of net new capital in Q3 2015, opening 130 new positions and adding to 120 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 89% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Lipocine, an estimated $7.13M trimmed.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.